NCT06933043已完成1 期
A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous NAV-240 in Healthy Participants
Navigator Medicines, Inc.1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2025年5月20日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Presence and severity of any treatment-emergent adverse events (TEAEs) and Serious Adverse Events (SAEs)
研究概览
简要总结
The goal of this clinical trial is to assess initial safety/tolerability of multiple doses of drug NAV-240. It will also learn about the profile and immunogenicity of drug NAV-240. The main question it aims to answer is:
• What medical problems do participants have when taking multiple doses of drug NAV-240? Researchers will compare drug NAV-240 to a placebo (a look-alike substance that contains no drug) to see if any medical problems participants have differ between those taking drug NAV-240 and those taking placebo.
详细描述
This randomized, double-blind, placebo-controlled, multiple ascending dose (MAD) study will evaluate the safety, tolerability, pharmacokinetics (PK)/pharmacodynamics (PD), and immunogenicity of NAV-240.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Selected Inclusion Criteria:
- •Male and female participants 18 - 65 years of age
- •Medically healthy, in the opinion of the Investigator, with no clinically significant findings on medical history, physical examination, vital signs, or electrocardiograms (ECGs) at Screening, and/or before administration of the initial dose of study drug.
- •Participants must have clinical laboratory values within normal ranges of upper limit of normal (ULN) as specified by the testing laboratory, unless deemed not clinically significant (NCS) by the Investigator.
- •Body mass index (BMI) 18 to ≤35 kg/m2 at Screening.
- •Female participants of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day -
- •Female participants of childbearing potential who are sexually active with a male partner of reproductive potential must agree to the use highly effective method of contraception established from at least 28 days prior to screening until at least 90 days after study drug dosing.
- •Male participants with female partners who are of reproductive potential must agree to the use of a male condom PLUS a highly effective, method of contraception for the duration of the study, and for at least 90 days after study drug dosing. Male healthy participants also must agree to refrain from sperm donation during the study and for at least 90 days after study drug dosing. Note: Males who are surgically sterile (i.e., documented successful vasectomy) will also be required to use a male condom. Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the participant.
- •Participants must provide signed informed consent prior to study entry and have the ability and willingness to attend and comply with the necessary visits at the study site. They must also receive a copy of the fully executed informed consent document.
排除标准
- •A relevant history of severe respiratory disease that required treatment and/or follow up under the direction of a physician.
- •Any neurological, psychiatric, vascular, or system disorder that could also affect the evaluation of disease activity assessments.
- •Any other significant acute or chronic medical illness that, in the opinion of the Investigator, would impact the participant's ability to complete all study requirements or that might impact the assessment of study data, or the participant has had a clinically significant illness within 30 days prior to study drug dosing per the Investigator's discretion.
- •History of alcoholism or drug abuse within the prior 2 years.
- •Acute COVID infection (within three months of Screening) or long COVID.
- •A history and/or current presence of a clinically significant atopic allergy, hypersensitivity, or allergic reactions.
- •Known or suspected clinically relevant drug hypersensitivity to any components of the test and reference investigational product formulation or comparable drugs.
- •A history of any infection requiring hospitalization, IV or oral antibiotics, or as otherwise judged clinically significant, within the 3 months prior to Screening, or an opportunistic infection within the past 12 months, or ongoing infection including chronic viral disease.
- •A positive test result for drugs of abuse, cotinine, or alcohol at Screening and on Day -
- •Active tuberculosis (TB) or a history of TB, or a positive TB blood test at Screening.
- •Systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg confirmed by repeat.
- •Abnormalities on 12-lead echocardiogram (ECG) prior to study drug dosing, confirmed by repeat.
- •All prescription and over-the-counter medications (including vitamins and dietary or herbal supplements), except for contraceptives and acetaminophen, as needed, are prohibited within 7 days prior to the first study drug administration and throughout the treatment period of the study.
- •Received vaccines (whether live, attenuated, or killed/inactivated) within 4 weeks prior to Day 1 or is planning to receive any vaccine over the course of the study. Note, influenza vaccines (inactivated) will be allowed during the study.
- •Received anti-TNF therapy in the past, confirmed by participant and Investigator.
- •Receipt of any investigational drug within 30 days prior to Screening or 5 half-lives, whichever is longer.
- •Females who are pregnant or breastfeeding.
- •Active cigarette smoker or has regularly used nicotine or nicotine-containing products
- •Any reason which, in the opinion of the Investigator, would prevent the healthy participant from participating in the study.
研究组 & 干预措施
NAV-240
Experimental
Participants will be enrolled in 1 of 3 multiple ascending dose cohorts. Six participants in each cohort will receive NAV-240.
干预措施: NAV-240 (Drug)
Placebo to match NAV-240
Placebo Comparator
In each multiple ascending dose cohort, 2 participants will receive matching placebo.
干预措施: Placebo (Drug)
结局指标
主要结局
Presence and severity of any treatment-emergent adverse events (TEAEs) and Serious Adverse Events (SAEs)
时间窗: Through 6 weeks after last dose of study drug.
Incidence, nature, and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
次要结局
- Pharmacokinetics parameter - maximum observed concentration (Cmax)(Through to Day 99.)
- Pharmacokinetics parameter - Time for maximum observed Concentration (Tmax)(Through to Day 99.)
- Pharmacokinetics parameter - Area under the curve (AUC)(Through to Day 99.)
- Pharmacokinetics parameter - Volume of distribution (Vz)(Through to Day 99.)
- Immunogenicity of study drug - Anti-Drug Antibodies (ADAs)(Through to Day 99.)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A First-in-human Study of the Safety of an Immunosuppressive Antibody (IMP761) in Healthy VolunteersHealthyNCT06637865Immutep S.A.S.79
已完成
1 期
Safety, Tolerability, Pharmacokinetics And Measurement Of Whole Blood Activity (WBA) Of PNU-100480 After Multiple Oral Doses In Healthy Adult VolunteersTuberculosisNCT00990990Sequella, Inc.59
已完成
1 期
SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD SubjectsInflammatory Disorder of the Respiratory TractChronic Obstructive Pulmonary DisorderNCT02307162Verona Pharma plc112
已完成
1 期
Study of the Safety of Intravenous ArtesunateMalaria, CerebralMalariaNCT00292942U.S. Army Medical Research and Development Command26
已完成
1 期
A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Food Effect of HSG4112ObesityNCT04732988Glaceum90